Right ventricular involvement and the extent of left ventricular enhancement with magnetic resonance predict adverse outcome in pulmonary sarcoidosis

ESC Heart Failure

Volumn 5, Issue 1, 2018, Pages 157-171

  Smedema, Jan Peter ^a   van Geuns, Robert Jan ^b   Ector, Joris ^c   Heidbuchel, Hein ^d   Ainslie, Gillian ^e   Crijns, Harry J G M ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d HASSELT UNIVERSITY   (Belgium)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Cardiovascular magnetic resonance; Late gadolinium enhancement; Right ventricle; Risk stratification; Sarcoidosis

Indexed keywords

CARDIAC MUSCLE; CARDIOMYOPATHY; CINE MAGNETIC RESONANCE IMAGING; COMPLICATION; ETIOLOGY; FEMALE; FOLLOW UP; HEART RIGHT VENTRICLE FUNCTION; HEART VENTRICLE; HUMAN; INCIDENCE; LUNG SARCOIDOSIS; MALE; MIDDLE AGED; NETHERLANDS; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

CARDIOMYOPATHIES; FEMALE; FOLLOW-UP STUDIES; HEART VENTRICLES; HUMANS; INCIDENCE; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; MYOCARDIUM; NETHERLANDS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SARCOIDOSIS, PULMONARY; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 85049346634     PISSN: None     EISSN: 20555822     Source Type: Journal    
DOI: 10.1002/ehf2.12201     Document Type: Article

References (28)

1. Youssef G, Beanlands RSB, Birnie DH, Nery PB. Cardiac sarcoidosis: applications of imaging in diagnosis and directing treatment. Heart 2011; 97: 2078–2087.
2. Blankstein R, Osborn M, Naya M, Waller A, Ki CK, Murthy VL, Kazemian P, Kwong RY, Tokuda M, Skali H, Padera R, Hainer J, Stevenson WG, Dorbala S, Di Carli MF. Positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014; 63: 329–336.
3. Cheong BY, Muthupillai R, Nemeth M, Lambert B, Dees D, Huber S, Castriotta R, Flamm SD. The utility of delayed-enhancement magnetic resonance imaging for identifying non-ischemic myocardial fibrosis in asymptomatic patients with biopsy-proven systemic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26: 39–46.
4. Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, Meine TJ, White JB, Elliott MD, Kim HW, Judd RM, Kim RJ. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009; 120: 1969–1977.
5. Shafee MA, Fukuda K, Wakayama Y, Nakano M, Kondo M, Hasebe Y, Kawana A, Shimokawa H. Delayed enhancement on cardiac magnetic resonance imaging is a poor prognostic factor in patients with cardiac sarcoidosis. J Cardiol 2012; 60: 448–453.
6. Greulich S, Deluigi CC, Gloekler S, Wahl A, Zürn C, Kramer U, Nothnagel D, Bültel H, Schumm J, Grün S, Ong P, Wagner A, Schneider S, Nassenstein KM, Sechtem U, Bruder O, Mahrhold H. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. J Am Coll Cardiol Img 2013; 6: 501–511.
7. Crawford T, Mueller G, Sarsam S, Prasitdumrong H, Chaiyen N, Gu X, Schuller J, Kron J, Nour KA, Cheng A, Ji SY, Feinstein S, Gupta S, Lig K, Sinno M, Abu-Hashih S, Al-Mallah M, Sauer WH, Ellenbogen K, Morady F, Bogun F. Magnetic resonance imaging for identifying patients with cardiac sarcoidosis and preserved or mildly reduced left ventricular function at risk of ventricular arrhythmias. Circ Arrhythm Electrophysiol 2014; 7: 1109–1115.
8. Ise T, Hasegawa T, Morita Y, Yamada N, Funada A, Takahama H, Amaki M, Kanzaki H, Okamura H, Kamakura S, Shimizu W, Anzai T, Kitakaze M. Extensive late gadolinium enhancement on cardiovascular magnetic resonance predicts adverse outcomes and lack of improvement in LV function after steroid therapy in cardiac sarcoidosis. Heart 2014; 100: 1165–1172.
9. Nagai T, Kohsaka S, Okuda S, Anzai T, Asano K, Fukuda K. Incidence and prognostic significance of myocardial late gadolinium-enhancement in sarcoidosis patients without cardiac manifestation. Chest 2014; 146: 1064–1072.
10. Nadel J, Lancefield T, Voskoboinik A, Taylor AJ. Late gadolinium enhancement identified with cardiac magnetic resonance imaging in sarcoidosis patients is associated with long-term ventricular arrhythmia and sudden cardiac death. Eur Heart J Cardiovasc Imaging 2015; 16: 1634–1641.
11. Ekström K, Lehtonen J, Hänninen H, Kandolin R, Kivistö, Kupari M. Magnetic resonance imaging as a predictor of survival free of life-threatening arrhythmias and transplantation in cardiac sarcoidosis. J Am Heart Assoc 2016; 5: e003040.
12. Murtagh G, Laffin LJ, Beshai JF, Maffessanti F, Bonham CA, Patel AV, Yu Z, Addetia K, Mor-Avi V, Moss JD, Hogarth DK, Sweiss NJ, Lang RM, Patel AR. Prognosis in myocardial damage in sarcoidosis patients with preserved left ventricular ejection fraction. Risk stratification using cardiac magnetic resonance. Circ Cardiovasc Imag 2016; 9: e003738.
13. Agoston-Coldea L, Kouaho S, Sacre K. High mass (>18 g) of late gadolinium enhancement on CMR imaging is associated with major cardiac events on long-term outcome in patients with biopsy proven extra-cardiac sarcoidosis. Int J Cardiol 2016; 222: 950–956.
14. Yasuda M, Iwanaga Y, Kato T, Izumi T, Inuzuka Y, Nakamura T, Miyaji Y, Kawamura T, Ikeguchi S, Inoko M, Kurita T, Miyazaki S. Risk stratification for major adverse cardiac events and ventricular tachyarrhythmia's by cardiac MRI in patients with sarcoidosis. Open Heart 2016; 3: e000437.
15. Smedema JP, Snoep G, van Kroonenburgh MPG, van Geuns RJ, Dassen WR, Gorgels T, Crijns HJGM. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 2005; 45: 1683–1690.
16. Schuller JL, Zipse M, Crawford T, Bogun F, Beshai J, Patel AR, Sweiss NJ, Nguyen DT, Aleong RG, Varosy PD, Weinberger HD, Sauer WH. Implantable cardioverter defibrillator therapy in patients with cardiac sarcoidosis. J Cardiovasc Electrophysiol 2012; 23: 925–929.
17. Patel AR, Klein MR, Chandra S, Spencer KT, Decara JM, Lang RM, Burke MC, Garrity ER, Hogarth DK, Archer SL, Sweiss NJ, Beshai JF. Myocardial damage in patients with sarcoidosis and preserved left ventricular systolic function: an observational study. Eur J Heart Fail 2011; 13: 1231–1237.
18. Muser D, Santangeli P, Patahk RK, Castro SA, Liang JJ, Magnani S, Hayashi T, Garcia FC, Hutchinson MD, Supple GE, Frankel DS, Riley MP, Lin D, Schaller RD, Desjardins B, Dixit S, Callans DJ, Zado ES, Marchlinski FE. Long-term outcomes of catheter ablation of ventricular tachycardia in patients with cardiac sarcoidosis. Circ Arrhythm Electr 2016; 9: e004333.
19. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, Solomon SD, Louie EK, Schiller NB. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010; 23: 685–713.
20. Smedema JP, van Geuns RJ, Ainslie G, Ector J, Heibuchel H, Crijns HJGM. Right ventricular involvement in cardiac sarcoidosis demonstrated with cardiac magnetic resonance. ESC Heart Failure 2017, in print.
21. Gulati A, Ismail TF, Jabbour A, Alpendurada F, Guha K, Ismail NA, Raza S, Khwaja D, Brown TD, Morarji K, Liodakis E, Roughton M, Wage R, Pakrashi TC, Sharma R, Carpenter JP, Cook SA, Cowie MR, Assomull RG, Pennell DJ, Prasad SK. The prevalence and prognostic significance of right ventricular systolic dysfunction in non-ischemic dilated cardiomyopathy. Circulation 2013; 128: 1623–1636.
22. Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, Judson MA, Kron J, Mehta D, Cosedis Nielsen J, Patel AR, Ohe T, Raatikainen P, Soejima K. HRS Expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014; 11: 1305–1323.
23. rd, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeny MO, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Faxon DP, Halperin JL, Hiratzka LF, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura RA, Ornato JP, Page RL, Riegel B, Tarkington LG, Yancy CW. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices); American Association for Thoracic Surgery; Society of Thoracic Surgeons. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities. Circulation 2008; 117: e350–e408.
24. Jefic D, Joel B, Good E, Morady F, Rosman H, Knight B, Bogun F. Role of radiofrequency catheter ablation of ventricular tachycardia in cardiac sarcoidosis: report from a multi-centre registry. Heart Rhythm 2009; 6: 189–195.
25. Kandolin R, Lehtonen J, Airaksinen J, Vihinen T, Miettinen H, Kaikkonen K, Hataaja P, Kerola T, Kupari M. Cardiac sarcoidosis. Epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation 2015; 131: 624–1632.
26. Zhou Y, Lower EE, Li H, Farhey Y, Baughman RP. Cardiac sarcoidosis: the impact of age and implanted devices on survival. Chest 2017; 151: 139–148.
27. Crouser ED, Ono C, Tran T, He X, Raman SV. Improved detection of cardiac sarcoidosis using magnetic resonance with myocardial T2 mapping. Am J Resp Crit Care Med 2014; 189: 109–112.
28. Greulich S, Kitterer D, Latus J, Aguor E, Steubing H, Kaesemann P, Patrascu A, Greiser A, Groeninger S, Mayr A, Braun N, Alscher MD, Sechtem U, Mahrhold H. Comprehensive cardiovascular magnetic resonance assessment in patients with sarcoidosis and preserved left ventricular ejection fraction. Circ Cardiovasc Imaging 2016; 9: e005022.